VistaGen Therapeutics, Inc. VTGN Income Statement

Vistagen therapeutics, inc. (VTGN)

Income statement / TTM

Dec'19	Sep'19	Jun'19	Mar'19	Dec'18	Sep'18	Jun'18	Mar'18	Dec'17	Sep'17	Jun'17	Mar'17	Dec'16	Sep'16	Jun'16	Mar'16	Dec'15	Sep'15	Jun'15	Mar'15	Dec'14	Sep'14	Jun'14	Mar'14	Dec'13	Sep'13	Jun'13	Mar'13	Dec'12	Sep'12	Jun'12	Mar'12	Dec'11	Sep'11	Jun'11	Mar'11	Dec'10	Sep'10	Jun'10
Sublicense fees
-	-	-	-	-	-	-	-	-	-	-	1,250	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Grant revenue
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	200	669	671	988	1,342	1,226	1,808	1,891	2,071	0	0	0
Collaboration revenue
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	0	0	0	0	0	0	0	0	0	0
Other
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	0	0	0	0	0	0	0	0	0	0
Total revenues
-	-	-	-	-	-	-	-	-	-	-	1,250	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	200	669	671	988	1,342	1,226	1,808	1,891	2,071	0	0	0
Operating expenses:
Research and development
-	-	-	17,098	-	-	-	7,763	6,286	6,295	5,474	5,204	5,140	4,335	4,385	3,932	0	0	0	-	-	-	-	-	-	-	-	0	-	-	5,227	5,388	5,425	4,566	4,031	3,678	0	0	0
Research and development
0	0	0	-	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	0	-	-	-	-	-	0	0	-	-	-	-	-	-	-	-	-
Acquired in-process research and development
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	-	-	-	-	-	-	-	-	-
Acquired in-process research and development
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	0	0	0	0	0	0	0
General and administrative
7,968	6,877	7,901	7,458	6,934	6,343	6,739	6,437	6,384	7,394	6,321	6,295	12,312	11,372	13,609	13,919	8,835	8,170	4,995	4,344	2,524	2,750	2,740	2,548	3,180	3,082	3,111	3,562	3,858	4,607	4,925	4,997	4,771	5,889	5,564	4,957	0	0	0
Total operating expenses
23,260	24,489	26,570	24,556	22,912	18,588	16,150	14,200	12,670	13,689	11,795	11,499	17,452	15,707	17,994	17,851	12,626	11,600	7,327	6,777	4,567	4,898	4,999	5,029	5,434	5,904	6,371	6,993	8,777	9,712	10,152	10,385	10,197	10,455	9,595	8,635	0	0	0
Loss from operations
-23,260	-24,489	-26,570	-24,556	-22,912	-18,588	-16,150	-14,200	-12,670	-12,439	-10,545	-10,249	-16,202	-15,707	-17,994	-17,851	-12,626	-11,600	-7,327	-6,777	-4,567	-4,898	-4,999	-5,029	-5,434	-5,904	-6,371	-6,793	-8,108	-9,041	-9,164	-9,043	-8,971	-8,647	-7,703	-6,564	0	0	0
Other income (expenses), net:
Interest income (expense), net
-	-	0	-	-	-	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Interest income (expense), net
0	0	-	8	0	0	-	9	9	8	6	5	5	7	18	771	-1,596	-806	-213	-183	1,679	526	-402	-1,503	-1,309	-1,183	-1,133	-920	-867	-1,087	-1,264	-1,893	-769	695	1,856	3,119	0	0	0
Change in warrant liability
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	1,895	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Change in warrant liability
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-3,419	-3,725	-4,712	-3,489	-3,567	-1,830	467	546	2,351	357	0	0	78	31	-113	-115	-203	0	0	0
Loss on extinguishment of accounts payable
0	-	-	-23	0	-	-	-135	0	0	0	-	-	-	-	-26,700	-26,717	-26,717	-26,671	-2,388	0	0	0	-	-	-	-	-3,568	-3,537	-1,193	-1,193	-1,193	-1,193	0	0	-	0	-	-
Other expense
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-2	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Loss before income taxes
-	-	-	-24,587	-	-	-	-14,344	-12,814	-12,447	-10,551	-10,254	-16,207	-15,716	-19,663	-47,219	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Other expense
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	-	-	-	-	-	-	35	0	0	0	0	-0	-0	-0	-0	0	0	0
Loss before income taxes
0	0	0	-	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-13,884	-9,488	-8,266	-7,704	-2,965	-4,909	-10,373	-10,869	-12,882	-12,154	-11,321	-11,622	-12,207	-12,702	-11,594	-10,908	-9,480	0	0	0
Income taxes
2	2	2	2	2	2	2	2	2	2	2	0	0	0	0	2	2	2	2	-2	-2	-2	-2	-3	-3	-4	-4	0	0	1	1	1	1	1	3	1	0	0	0
Net loss and comprehensive loss
-23,230	-24,485	-26,584	-24,589	-22,945	-18,733	-16,295	-14,346	-12,816	-12,449	-10,553	-10,256	-16,209	-15,718	-19,665	-47,221	-44,941	-43,884	-38,857	-13,886	-9,490	-8,269	-7,707	-2,968	-4,912	-10,378	-10,874	-12,886	-12,158	-11,323	-11,624	-12,209	-12,703	-11,596	-10,911	-9,482	0	0	0
Accrued dividends on Series B Preferred stock
-	-	-	1,140	-	-	-	1,030	1,005	980	964	1,257	1,700	2,093	2,467	2,140	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Accrued dividends on Series B Preferred stock
0	0	0	-	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Deemed dividend from trigger of down round provision feature
-	-	-	-	-	-	-	-199	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Deemed dividend on Series B Preferred Units
-	-	-	-	-	-	-	-	-	-	-	111	357	1,026	1,913	2,058	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Deemed dividend on Series B Preferred Units
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Deemed dividend from trigger of down round provision feature
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	-	-	-	-	-	-	-	-	-	-
Net loss attributable to common stockholders
-24,459	-25,683	-27,752	-25,728	-24,056	-20,015	-17,551	-15,575	-14,020	-13,429	-11,517	-11,624	-18,266	-18,837	-24,045	-51,419	-48,211	-45,854	-39,325	-13,885	0	0	0	-	-	-	-	-	0	-	-	-	-	-	-	-	-	-	-
Basic and diluted net loss attributable to common stockholders per common share
-0.15	-0.13	-0.15	-0.17	-0.24	-0.30	-0.20	-0.19	-0.25	-0.53	-0.28	-0.32	-0.34	-0.42	-0.51	-4.44	-1.95	-5.26	-19.23	-	-	-	-3.70	-	-	-	-	-	-	-0.12	-	-	-	-	-	-	-	-	-
Weighted average shares used in computing basic and diluted net loss attributable to common stockholders per common share
43,158	42,622	42,622	35,113	30,696	25,815	22,987	22,880	13,895	9,892	9,034	8,602	8,381	8,047	5,097	2,123	1,765	1,624	1,559	-	-	-	1,229	-	-	-	-	-	-	17,094	-	-	-	-	-	-	-	-	-
Comprehensive loss
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	-	-	-	-	-	-	-	-	-
Basic net loss attributable to common stockholders per common share (in dollars per share)
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-4.24	-0.84	-1.58	-	-1.57	0.12	-1.35	0.18	-	-0.85	-	-0.11	-	-	-	-	-	-	-	-
Deemed dividend on Series A Preferred stock
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	-	-	-	-	-	-
Net loss attributable to common stockholders
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	-	-	-	-	-	-
Diluted net loss attributable to common stockholders per common share (in dollars per share)
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-4.24	-1.08	-1.90	-	-1.57	-0.44	-1.37	-0.44	-0.19	-0.85	-	-0.11	-0.18	-0.28	-0.15	-0.22	-0.67	-0.65	-0.30	-0.19
Basic net loss attributable to common stockholders per common share (in shares)
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	1,302	1,279	-	-	-	-	-	-	18,292	-	16,842	-	-	-	-	-	-	-	-
Diluted net loss attributable to common stockholders per common share (in shares)
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	1,466	1,302	1,299	-	1,162	1,110	1,128	1,061	20,236	18,292	-	16,842	16,562	16,035	15,241	11,105	5,243	5,240	5,241	5,240
Comprehensive loss
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-11,624	-12,209	0	0	0	-	-	-	-